Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05170724
Status
Available

Conditions

  • Chronic Spontaneous Urticaria

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Remibrutinib — DRUG
    Remibrutinib should be taken in accordance with the recommendations in the treatment plan.

Study Details

The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide access to remibrutinib for adult patients with chronic spontaneous urticaria (CSU)

Key Dates

First listed
Dec 28, 2021
Status verified
Dec 2025

Central Contacts

  • MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs
    1-888-669-6682
    [email protected]
  • Novartis Pharmaceuticals

Related Studies